Search All News
Columbia-led study hold promise for helping people find therapies that work.
Studies indicate that 29% to 46% of patients diagnosed with major depressive disorder show partial or no response to treatments.
This year’s Eric D. Hadar Distinguished Lecturer, Dr. Rajita Sinha, will present “Can We Rescue Stress and Trauma Related Pathophysiology in Addiction to Improve Treatment Outcomes?” on Nov. 16, 2022.
Patients who participate in fewer than two visits early in treatment are at risk for relapse, overdose, and possible death.
Source:MedscapeJune 10, 2019
“As we treat more people with ketamine, an unfortunate side effect of that is more exposure, which means that we're going to create more ketamine addicts,” said Dr. Drew Ramsey.
Source:Brooklyn EagleApril 17, 2019
Dr. J. John Mann says while there are clear short-term benefits to ketamine, its long-term effects, its abuse potential and the optimal number of treatments a patient should receive are still unknown.
- April 15, 2019
Columbia Psychiatrists suggest that researchers, pharmaceutical companies, and the FDA reconsider placebo-controlled, relapse prevention studies in schizophrenia.
Source:JAMAApril 10, 2019
Dr. Jeffrey Lieberman and colleagues conclude that the time has come to cease the use of placebo in relapse prevention studies and encourage the use of active comparators.
- April 4, 2019
Dr. Christine Ann Denny’s laboratory is interested in the molecular mechanisms underlying learning and memory.
Source:MD MagazineMarch 8, 2019
Dr. Jeffrey Lieberman’s concerns about whether dosing strategies for ketamine have been properly set by clinical trials are mentioned in this Q&A.
Source:NewsDayFebruary 23, 2019
Schizophrenia and other psychotic disorders affect each person differently and vary in severity, said Dr. Lisa Dixon.
Source:HealioFebruary 21, 2019
“The effectiveness of combinations of antipsychotic medications remains unclear; reviews of this treatment strategy agree on the need for further investigation,” Dr. T. Scott Stroup and team wrote.
- February 20, 2019
Patients with schizophrenia are often treated with more than one type of psychiatric medication, but a new study suggests that some combinations may be more effective than others.
Source:HealioFebruary 20, 2019
Dr. J. John Mann writes that ketamine “has a fairly robust effect on reducing suicidal ideation.”